Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Wednesday, August 26, 2015

Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim



 febrile neutropenia (FN)
 

abstract/open access
 Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy

..... The current data available on efficacy and safety on pegfilgrastim administration appear to be variable and based on several factors, including tumor types, disease sites, and chemotherapy regimens. The literature appears to be inconclusive overall. Our study sought to determine the safety and efficacy of pegfilgrastim administration scheduling in a population of women with gynecologic malignancies, and the results of this investigation have a potentially overarching impact on the primary and secondary prophylaxis of FN in this disease group. These results demonstrate no increased risk for the development of FN associated with pegfilgrastim administration on the same day as chemotherapy. However, the incidence of FN was low, and the aRRs could not be calculated. This is particularly exciting for the outpatient treatment of gynecologic malignancy in patients required to travel large distances to and from their treating facilities as it will eliminate a clinic visit. This change in practice to same-day administration of pegfilgrastim has potential financial ramifications, but further investigation is needed before this can be confirmed. Definitive evidence to support same-day administration of pegfilgrastim can be provided only with a prospective study. However, our findings support that same-day administration of pegfilgrastim is not inferior to standard administration in terms of treatment delay; however, this cannot be said for dose modification and hematologic toxicities. Our results support the option of same-day dosing to clinicians and patients who accept a possible decrement in dose modification and hematologic toxicity in exchange for convenience of administration. These data do contribute to the existing literature and can be utilized to support same-day use, which may improve patient satisfaction without compromising timing of delivery of treatment, an important goal of health care administration.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.